Pär-Ola Larsson new CEO of CarpoNovum

The board of directors have appointed Pär-Ola Larsson as new CEO of CarpoNovum, starting in April 2022.

Pär-Ola has a long experience working with Healtcare and Medical Service, both in Sweden and internationally. He has studied economics and marketing at the School of Economics in Gothenburg University, and holds an EMBA from Copenhagen Business School (CBS). He also has more than 15 years of experience from Boston Scientific and Johnson & Johnson, doing business development, marketing and sales, and working close to different stapling techniques. Pär-Olas most recent position was head of Marketing and Sales at XVIVO Perfusion AB.

New PMCF Study to start in 2022

In 2022, CarpoNovum will start a European ​Multicenter Post Market Clinical Follow-up study (outside Sweden) on the C-REX® system.​

As part of this we will be hosting workshops throughout the year. These workshops serve a first step for surgeons to get accreditation for use of C-REX® products. ​

C-REX clinical study in Stockholm delayed due to Covid-19

Due to unprecedented situation in Stockholm region caused by the Covid-19 outbreak, the C-REX clinical study has been delayed until further notice.

The scope of the study and the intention to enroll two hundred patients undergoing colon and rectum resections in Stockholm region remains unchanged.